GlassScriptPhysician profile
Neha Chawla
NPI 1902056021
$7,979.12
in general payments reported to CMS, 2019-2025
46 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $71.12 · 2021: $729 · 2022: $806 · 2023: $927 · 2024: $2,301 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,260 · Food and Beverage: $2,334 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,260.00 |
| Food and Beverage | $2,334.25 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,709.64 | 2019-2024 | Alunbrig |
| Beone Medicines USA, INC. | $1,665.27 | 2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $679.83 | 2019-2025 | Opdivo, Augtyro, Opdualag |
| Janssen Biotech, INC. | $473.45 | 2019-2024 | Darzalex, Tecvayli, Akeega |
| Novartis Pharmaceuticals Corporation | $400.96 | 2019-2025 | |
| Pfizer INC. | $245.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $238.15 | 2021-2024 | Lokelma, Enhertu, Imfinzi |
| Seagen INC. | $233.62 | 2020-2023 | Tukysa |
| Celgene Corporation | $229.83 | 2021-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $199.95 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $169.50 | 2021-2023 | Imbruvica |
| Sirtex Medical INC | $157.95 | 2019 | |
| Boston Scientific Corporation | $148.36 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Lilly USA, LLC | $145.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $142.53 | 2019-2025 | Keytruda, Welireg, Lynparza |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $127.19 | 2019-2025 | |
| Eisai INC. | $77.26 | 2020-2024 | |
| Gilead Sciences, INC. | $77.16 | 2019-2024 | |
| Stemline Therapeutics INC. | $76.59 | 2024-2025 | Orserdu |
| Beigene USA, INC. | $62.67 | 2022-2023 | Brukinsa |
| Adc Therapeutics America, INC. | $60.98 | 2023-2025 | |
| Incyte Corporation | $60.47 | 2019-2023 | Jakafi |
| Exelixis INC. | $59.61 | 2022-2025 | Cabometyx |
| Daiichi Sankyo INC. | $50.45 | 2023-2024 | Enhertu, Injectafer |
| Array Biopharma INC | $50.24 | 2022-2023 | Lorbrena, Xalkori, Mektovi |
| Genentech USA, INC. | $42.19 | 2022-2025 | Phesgo, Venclexta |
| Amgen INC. | $39.04 | 2019-2021 | |
| Astellas Pharma US INC | $34.40 | 2019-2022 | |
| Taiho Oncology, INC. | $32.95 | 2023-2024 | |
| Emd Serono, INC. | $30.90 | 2022-2024 | |
| Novocure INC. | $24.27 | 2025 | Optune Gio |
| Dendreon Pharmaceuticals LLC | $19.80 | 2025 | Provenge |
| Apellis Pharmaceuticals, INC. | $19.73 | 2024 | Empaveli |
| Alexion Pharmaceuticals, INC. | $18.73 | 2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $17.53 | 2025 | Xpovio |
| Kite Pharma, INC. | $17.12 | 2023 | Yescarta |
| Pharmaessentia USA Corporation | $16.26 | 2024 | Besremi |
| Agios Pharmaceuticals, INC. | $15.12 | 2025 | Pyrukynd |
| Myovant Sciences INC. | $14.62 | 2021 | |
| Immunogen, INC. | $14.56 | 2024 | Elahere |
| Regeneron Healthcare Solutions, INC. | $14.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.51 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.46 | 2019 | |
| Tesaro, INC. | $13.91 | 2019 | |
| Foundation Medicine, INC. | $12.84 | 2019 | |
| Rigel Pharmaceuticals, INC. | $9.16 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.